EG13926A - An isoxazole derivatives processes for its preparation compositions containing it and its use for combating rheumatism - Google Patents

An isoxazole derivatives processes for its preparation compositions containing it and its use for combating rheumatism

Info

Publication number
EG13926A
EG13926A EG748/79A EG74879A EG13926A EG 13926 A EG13926 A EG 13926A EG 748/79 A EG748/79 A EG 748/79A EG 74879 A EG74879 A EG 74879A EG 13926 A EG13926 A EG 13926A
Authority
EG
Egypt
Prior art keywords
rheumatism
combating
compositions containing
preparation compositions
isoxazole derivatives
Prior art date
Application number
EG748/79A
Other languages
English (en)
Inventor
Friederich Johannes D Kammerer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of EG13926A publication Critical patent/EG13926A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG748/79A 1978-12-16 1979-12-12 An isoxazole derivatives processes for its preparation compositions containing it and its use for combating rheumatism EG13926A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (1)

Publication Number Publication Date
EG13926A true EG13926A (en) 1982-09-30

Family

ID=6057414

Family Applications (1)

Application Number Title Priority Date Filing Date
EG748/79A EG13926A (en) 1978-12-16 1979-12-12 An isoxazole derivatives processes for its preparation compositions containing it and its use for combating rheumatism

Country Status (25)

Country Link
US (2) US4284786A (da)
EP (1) EP0013376B1 (da)
JP (1) JPS5583767A (da)
AR (2) AR222680A1 (da)
AT (1) ATE1067T1 (da)
AU (1) AU529341B2 (da)
BG (1) BG60764B2 (da)
CA (1) CA1129867A (da)
DE (2) DE2854439A1 (da)
DK (1) DK149886C (da)
EG (1) EG13926A (da)
ES (2) ES486758A1 (da)
FI (1) FI64154C (da)
GR (1) GR72731B (da)
HU (1) HU178015B (da)
IE (1) IE49126B1 (da)
IL (1) IL58951A (da)
LU (1) LU90466I2 (da)
MX (2) MX6174E (da)
NL (1) NL990037I2 (da)
NO (1) NO148925C (da)
NZ (1) NZ192400A (da)
PH (1) PH16627A (da)
PT (1) PT70596A (da)
ZA (1) ZA796793B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
DD297328A5 (de) 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
DK0607776T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
TW314467B (da) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
ES2148561T3 (es) * 1994-10-17 2000-10-16 Aventis Pharma Ltd Prevencion y curacion de enfermedades alergicas de tipo i.
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
KR20020067545A (ko) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
US20020077485A1 (en) * 2000-08-14 2002-06-20 Ilya Avrutov Micronized leflunomide
ATE396719T1 (de) 2001-04-05 2008-06-15 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20030139606A1 (en) * 2001-11-09 2003-07-24 Ray Anup Kumar Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
CN101242831A (zh) * 2005-08-31 2008-08-13 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
BR112022017754A2 (pt) 2020-03-06 2022-10-18 Actelion Pharmaceuticals Ltd Métodos para retardar a perda de volume cerebral
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
US20240261268A1 (en) 2022-02-11 2024-08-08 Vanda Pharmaceuticals Inc. Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
ATE1067T1 (de) 1982-06-15
AR222680A1 (es) 1981-06-15
NO794094L (no) 1980-06-17
GR72731B (da) 1983-12-01
EP0013376A2 (de) 1980-07-23
LU90466I2 (fr) 2000-01-03
JPS5583767A (en) 1980-06-24
NO148925B (no) 1983-10-03
NL990037I1 (nl) 2000-01-03
NO148925C (no) 1984-01-11
DE2962929D1 (en) 1982-07-08
JPH0133470B2 (da) 1989-07-13
MX6174E (es) 1984-12-04
FI793899A (fi) 1980-06-17
FI64154B (fi) 1983-06-30
DK149886C (da) 1987-04-21
IE792426L (en) 1980-06-16
IL58951A (en) 1984-01-31
DK534279A (da) 1980-06-17
ES486750A1 (es) 1980-06-16
PH16627A (en) 1983-12-05
DE2854439A1 (de) 1980-07-03
BG60764B2 (bg) 1996-02-29
AR226894A1 (es) 1982-08-31
AU5385379A (en) 1980-06-19
FI64154C (fi) 1983-10-10
EP0013376B1 (de) 1982-05-19
NZ192400A (en) 1982-02-23
AU529341B2 (en) 1983-06-02
CA1129867A (en) 1982-08-17
US4351841A (en) 1982-09-28
NL990037I2 (nl) 2000-01-03
PT70596A (de) 1980-01-01
HU178015B (en) 1982-02-28
ES486758A1 (es) 1980-05-16
IE49126B1 (en) 1985-08-07
DK149886B (da) 1986-10-20
EP0013376A3 (en) 1980-09-17
IL58951A0 (en) 1980-03-31
ZA796793B (en) 1980-11-26
US4284786A (en) 1981-08-18
MX8403A (es) 1994-03-31

Similar Documents

Publication Publication Date Title
EG13926A (en) An isoxazole derivatives processes for its preparation compositions containing it and its use for combating rheumatism
DE2962923D1 (en) Preparation of n-substituted derivatives of 1-deoxy-nojirimycine
PT66076A (en) Process for the preparation of herbicide compounds and compositions
IL60555A0 (en) Pharmaceutical compositions containing certain ureal derivatives
PT66040B (en) Process for the preparation of sweetening compounds and compositions
GR65650B (en) Derivatives of pyrazolic ethers,method for the preparation thereof and parasiticides containing these compounds
PT67009B (en) Processes for the preparation of pharmaceutical compositions
IL60890A (en) Preparation for the treatment of theileriosis containing piperidylacetonylquinazolinone derivatives and some new such compounds
GB2017681B (en) Derivatives of 3-phenyl-3-phenoxy-propanamine
DE3072103D1 (en) Pharmaceutical compositions containing 3-amino-pyrazoline derivatives
MY8600272A (en) Thiourea derivatives and isathiourea derivatives processes for their preparation agents containing these compounds and their use for combating pests
NZ192927A (en) Hydroxy derivatives of 2-isopropylamino-pyrimidine pharmaceutical compositions
ZA796201B (en) Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
PH18056A (en) Pharmaceutical formulations of cisplatin
ZA791053B (en) 1-oxo-1hpyrimido benzthiazole derivatives processes for thheir preparation and pharmaceutical compositions containinning these compounds
ZA804667B (en) Chemical compositions for treatment of pseudo-folliculitis
ZA757990B (en) Stabilized formulations of 2-alkoxyiminon-carbamoyl-2-cyanoacetamides
ZA793923B (en) Medicinal formulation
DE2962567D1 (en) N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them
IL58621A0 (en) Pharmaceutical compositions comprising aryltrifluoroethanol derivatives
NZ189899A (en) Dilignols and dilignol-type compounds pharmaceutical compositions
IL57476A0 (en) Compounds of the muramy-peptide type and pharmaceutical compositions containing them
GB2025422B (en) 17-acetylene derivatives of androst-4-ene
GB2041915B (en) Preparation of bromo-p-terphenyl derivatives
IL56815A (en) Epimerisation of 3-vinylpiperidine derivatives